Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer
A phase 3 trial of PSMA-1007 F-18 run by ABX advanced biochemical compounds GmbH in prostate cancer, now recruiting.
Overview
Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer is a phase 3 interventional study registered as NCT06122584 by ABX advanced biochemical compounds GmbH, with 380 participants planned, started 2024-06-13. Conditions listed: Prostate Cancer. No results are recorded here; the registry entry is the source.
Setting
Prospective, Multi-Center Study to Assess the Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed High-Risk or Very-High-Risk Prostate Cancer
Phase
Phase 3
Sponsor
ABX advanced biochemical compounds GmbH
Registry
Enrolled
380
Similar pages
not linked directly; found by shared links- TechnologyPSMA PET
Shares PSMA-1007 F-18, ABX advanced biochemical compounds, Prostate cancer.